CDX2 and colorectal cancer: Among the genes involved in DNA damage response and repair, TP53 is often mutated in colorectal cancers and was more often mutated in non-CDX2-suppressed cases (69.6%) compared with CDX2-suppressed cases (44.6%, Fisher’s exact test p = 0.0004, Figure 5).